Novamind is adding a second Client Care Center as it expands its clinic network from four to eight locations.
Novamind is adding a second Client Care Center as it expands its clinic network from four to eight locations.
Cybin announces approval to enter its Phase IIa clinical study and defines the scope of the clinical trial.
The FDA has approved the use of MDMA by therapists -- to better prepare them to administer MDMA-assisted psychotherapy.
MindMed reports a net loss of CAD$14 million for Q1, with US$160 million in cash and a total cash burn for the quarter of CAD$10 million.
Traumatic Brain Injury is another major treatment market targeted by psychedelics R&D. TBIs are now a health crisis in many professional sports. Opportunity knocks.
Numinus fills several key roles including a new Director of Mergers and Acquisitions and a new Chief Communications Officer.
Compass Pathways highlights for Q1 include two new patents and reports its Phase IIb clinical trial is on track.
Wesana inks a multi-year research agreement with the World Boxing Council on psychedelics therapy for Traumatic Brain Injury (TBI).
For a solid month, there has been an explosion in coverage of the psychedelic drug industry by the mainstream media.
Optimi Health and Numinus Wellness announce a new milestone in their partnership to develop an all-natural psilocybin extract.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now